Microbix announces extension of agreement with major vaccine producer
Microbix Biosystems Inc. has extended its agreement with a major international vaccine producer, whereby the two companies will continue to collaborate in evaluating Microbix' proprietary technology designed to significantly boost the production yield of flu vaccine.
The initial evaluation period was to expire June 30, 2005. Microbix' partner has now been granted an additional 90-day period to continue testing the technology.
"During this extension, the Company and its partner will also be negotiating the final terms of the definitive licensing agreement," said William J. Gastle, President and CEO. Should the companies enter into a definitive licensing agreement, Microbix will receive milestone payments and royalties on worldwide sales of product using Microbix' technology.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.